<div id="readability-page-1"><p>Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) shares traded down 2.7% during mid-day trading on Wednesday . The stock traded as low as $36.88 and last traded at $37.16. 85,240 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 558,863 shares. The stock had previously closed at $38.21.</p><div><p><span></span><span>Get <strong>Apogee Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><ul><li>IPO watch 2024: Which new stocks will hit the market?</li></ul><p>Several equities analysts have issued reports on the company. Stifel Nicolaus lifted their target price on Apogee Therapeutics from $46.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Bank of America initiated coverage on Apogee Therapeutics in a research note on Friday, May 10th. They issued a &#34;buy&#34; rating and a $80.00 target price on the stock. Guggenheim boosted their price target on Apogee Therapeutics from $44.00 to $91.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Wedbush restated an &#34;outperform&#34; rating and set a $87.00 price target on shares of Apogee Therapeutics in a research note on Monday, May 13th. Finally, Jefferies Financial Group boosted their price target on Apogee Therapeutics from $37.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and an average target price of $73.00.</p><p><b>View Our Latest Report on APGE</b></p><h2>Apogee Therapeutics Trading Down 1.9 %</h2><p>The stock has a fifty day moving average of $45.85 and a 200 day moving average of $44.48. </p><p>Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.04). Analysts expect that Apogee Therapeutics, Inc. will post -2.64 EPS for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently bought and sold shares of APGE. EntryPoint Capital LLC increased its position in shares of Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $212,000. Ameritas Investment Partners Inc. lifted its stake in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock valued at $274,000 after purchasing an additional 2,172 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $339,000. Finally, Virtu Financial LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $362,000. 79.04% of the stock is owned by institutional investors and hedge funds. </p><h2>About Apogee Therapeutics</h2> (Get Free Report)<p>Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Apogee Therapeutics</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>AbbVie Stock: A Perfect Dip for Investors to Buy</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Forget NVIDIA: Super Micro Computer Stock Leads in Momentum</li><li>What Is WallStreetBets and What Stocks Are They Targeting?</li><li>GitLab Stock Rebounds: The Inside Story of Its Comeback</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ [Breakthrough] The &#34;Drug Smuggler&#34; Curing Brain Disease? <span><span>(From Behind the Markets)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx"/></p><h2>Should you invest $1,000 in Apogee Therapeutics right now?</h2><p>Before you consider Apogee Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.</p><p>While Apogee Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

APGE

<p>Apogee Therapeutics (NASDAQ:APGE) shares declined by 2.7% during mid-day trading. The stock traded at a low of $36.88 and last traded at $37.16. The average session volume saw a decline of 85% with 85,240 shares changing hands. The stock has a fifty day moving average of $45.85 and a 200 day moving average of $44.48. The company reported lower than expected earnings results for the quarter. Several analysts have rated the stock as a "buy" with an average target price of $73.00.</p>

Apogee Therapeutics (NASDAQ:APGE) Shares Down 2.7%